Whole-Brain Radiation in the Treatment of Brain Metastases in ALK-Positive Non-Small-Cell Lung Cancer Reply

被引：0
|
作者：
Rusthoven, Chad G. [1 ]
Doebele, Robert C. [1 ]
机构：
[1] Univ Colorado, Sch Med, Aurora, CO 80045 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2017年 / 35卷 / 07期
关键词：
STEREOTACTIC RADIOSURGERY; SURGICAL RESECTION; RADIOTHERAPY; THERAPY; CRIZOTINIB; MANAGEMENT; SURVIVAL; PHASE-3;
D O I：
10.1200/JCO.2016.70.9287
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：810 / 811
页数：2
相关论文
共 50 条
  • [21] Alectinib in resected ALK-positive non-small-cell lung cancer
    Gourmet, Anais
    Ferrari, Victoria
    BULLETIN DU CANCER, 2024, 111 (10) : 905 - 906
  • [22] Alectinib for advanced ALK-positive non-small-cell lung cancer
    Ly, Ashley C.
    Olin, Jacqueline L.
    Smith, Morgan B.
    AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2018, 75 (08) : 515 - 522
  • [23] Targeting brain metastases in ALK-rearranged non-small-cell lung cancer
    Zhang, Isabella
    Zaorsky, Nicholas G.
    Palmer, Joshua D.
    Mehra, Ranee
    Lu, Bo
    LANCET ONCOLOGY, 2015, 16 (13): : E510 - E521
  • [24] Phase II Trial of Erlotinib Plus Concurrent Whole-Brain Radiation Therapy for Patients With Brain Metastases From Non-Small-Cell Lung Cancer
    Welsh, James W.
    Komaki, Ritsuko
    Amini, Arya
    Munsell, Mark F.
    Unger, Wyatt
    Allen, Pamela K.
    Chang, Joe Y.
    Wefel, Jeffrey S.
    McGovern, Susan L.
    Garland, Linda L.
    Chen, Su S.
    Holt, Jamie
    Liao, Zhongxing
    Brown, Paul
    Sulman, Erik
    Heymach, John V.
    Kim, Edward S.
    Stea, Baldassarre
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (07) : 895 - 902
  • [25] Brain Metastases in Non-Small-Cell Lung Cancer
    Dawe, David E.
    Greenspoon, Jeffrey N.
    Ellis, Peter M.
    CLINICAL LUNG CANCER, 2014, 15 (04) : 249 - 257
  • [26] First-line treatment of advanced ALK-positive non-small-cell lung cancer
    Gandhi, Shipra
    Chen, Hongbin
    Zhao, Yujie
    Dy, Grace K.
    LUNG CANCER-TARGETS AND THERAPY, 2015, 6 : 71 - 82
  • [27] Brigatinib versus Crizotinib in ALK-Positive Non-Small-Cell Lung Cancer
    Camidge, D. R.
    Kim, H. R.
    Ahn, M. -J.
    Yang, J. C. -H.
    Han, J. -Y.
    Lee, J. -S.
    Hochmair, M. J.
    Li, J. Y. -C.
    Chang, G. -C.
    Lee, K. H.
    Gridelli, C.
    Delmonte, A.
    Garcia Campelo, R.
    Kim, D. -W.
    Bearz, A.
    Griesinger, F.
    Morabito, A.
    Felip, E.
    Califano, R.
    Ghosh, S.
    Spira, A.
    Gettinger, S. N.
    Tiseo, M.
    Gupta, N.
    Haney, J.
    Kerstein, D.
    Popat, S.
    NEW ENGLAND JOURNAL OF MEDICINE, 2018, 379 (21): : 2027 - 2039
  • [28] Treatment of ALK-Positive Non-Small Cell Lung Cancer
    Bang, Yung-Jue
    ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE, 2012, 136 (10) : 1201 - 1204
  • [29] Primary resistance to ALK inhibitor in ALK-positive non-small-cell lung cancer.
    Kang, Jin
    Chen, Huajun
    Zhou, Qing
    Tu, Hai-Yan
    Zhang, Xu-Chao
    Jian, Su
    Wang, Zhen
    Wang, Bin-Chao
    Wu, Yi-Long
    Yang, Jin-Ji
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [30] Systematic review of sequencing of ALK inhibitors in ALK-positive non-small-cell lung cancer
    Barrows, Stephanie M.
    Wright, Kelly
    Copley-Merriman, Catherine
    Kaye, James A.
    Chioda, Marc
    Wiltshire, Robin
    Torgersen, Knut Martin
    Masters, Elizabeth T.
    LUNG CANCER-TARGETS AND THERAPY, 2019, 10 : 11 - 20
12345